Windtree Therapeutics, Inc. (WINT)
Stock Price:
$6.67 USD
0.00 (0.00%)
Updated November 27, 1:00 PM EST - Market closed
Key Info
| Market Cap |
112.87M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-32.49M |
| Shares Out |
16.92M |
| EPS (ttm) |
-2.27 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
November 27 |
| Last Price |
$6.67 |
| Previous Close |
$6.67 |
| Change ($) |
0.00 |
| Change (%) |
0.00% |
| Day's Open |
6.19 |
| Day's Range |
6.19 - 6.69 |
| Day's Volume |
6,548 |
| 52-Week Range |
5.24 - 9.90 |
More Stats
| Market Cap |
112.87M |
| Enterprise Value |
94.39M |
| Earnings Date (est) |
Jan 1, 1970 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
16.92M |
| Float |
n/a |
| EPS (basic) |
-2.30 |
| EPS (diluted) |
-2.27 |
| FCF / Share |
-1.59 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
119,333 |
| Short Ratio |
7.92 |
| Short % of Float |
n/a |
| Beta |
0.11 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
1.42 |
| Revenue |
n/a |
| Operating Income |
-27.91M |
| Net Income |
-32.49M |
| Free Cash Flow |
-26.32M |
| Net Cash |
18.48M |
| Net Cash / Share |
1.09 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-15.41% |
| ROE |
-50.45% |
| ROIC |
-3,495.60% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (1)
| Buy |
1 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
12.3
Current: $6.67
High
12.3
Target: 12.25
*Average 12-month price target from 1 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 0.20 | 1.79 | 1.49 | 2.04 | 0.99 | 2.84 | 0.39 | 0.20 | 0.58 | - |
| Revenue Growth | -88.93% | 20.4% | -27.28% | 106.89% | -65.19% | 630.67% | 98.97% | -66.49% | - | - |
| Gross Profit | 0.20 | 1.79 | 1.49 | 2.04 | 0.06 | 0.16 | -0.13 | 0.20 | 0.58 | - |
| Operating Income | -24.89 | -16.20 | -22.55 | -38.04 | -39.83 | -43.26 | -44.51 | -37.82 | -24.51 | -25.53 |
| Net Income | -27.48 | -20.53 | -18.45 | -39.49 | -55.17 | -44.06 | -45.22 | -37.32 | -20.97 | -19.18 |
| Shares Outstanding | 10.93 | 1.50 | 0.34 | 0.14 | 0.12 | 0.10 | 0.07 | 0.05 | 0.03 | 0.01 |
| Earnings Per Share | -2.51 | -23.20 | -72.42 | -284.52 | -478.81 | -470.41 | -688.79 | -797.99 | -781.19 | -1,385.99 |
| Operating Cash Flow | -24.66 | -15.78 | -21.05 | -33.59 | -33.50 | -41.17 | -40.45 | -32.88 | -22.70 | -24.27 |
| Capital Expenditures | -0.19 | 0.01 | -0.02 | -0.25 | -0.19 | -0.78 | -0.61 | -0.64 | -0.11 | -0.10 |
| Free Cash Flow | -24.85 | -15.77 | -21.07 | -33.84 | -33.69 | -41.95 | -41.06 | -33.52 | -22.80 | -24.37 |
| Cash & Equivalents | 22.73 | 25.32 | 2.04 | 5.81 | 38.95 | 44.94 | 86.61 | 27.29 | 10.59 | 10.61 |
| Total Debt | 6.31 | 7.97 | - | 25.00 | 25.00 | 20.36 | 18.50 | 0.22 | 0.29 | 0.44 |
| Net Cash / Debt | 16.42 | 17.34 | 2.04 | -19.19 | 13.95 | 24.57 | 68.11 | 27.08 | 10.30 | 10.17 |
| Assets | 119 | 119 | 3.35 | 9.70 | 44.38 | 47.50 | 89.32 | 29.94 | 13.32 | 14.54 |
| Liabilities | 44.04 | 51.28 | 27.27 | 38.53 | 36.11 | 28.30 | 30.82 | 12.29 | 12.06 | 8.51 |
| Book Value | 74.94 | 68.11 | -23.92 | -28.83 | 8.27 | 19.20 | 58.50 | 17.65 | 1.26 | 6.03 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Windtree Therapeutics, Inc. |
| Country |
United States |
| Employees |
31 |
| CEO |
Craig E. Fraser |
Stock Information
| Ticker Symbol |
WINT |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: WINT |
| IPO Date |
August 8, 1995 |
Description
Windtree Therapeutics, a biotechnology and medical device company, engages in the research and development of products that focus on acute pulmonary and cardiovascular diseases. Its four lead development programs include istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome (RDS) in premature infants; lyophilized KL4 surfactant for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania.